Biomarker-directed therapies are improving outcomes for patients with early-stage non-small cell lung cancer (NSCLC) with driver mutations. Tune in to this webcast of a presentation from the 2024 American Oncology Network Summit. Gain valuable information as experts engage in a comprehensive discussion on the latest advances and provide essential insights that can inform individualized treatment for patients with early-stage NSCLC with driver mutations.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancing-biomarker-testing-inform-treatment-selection-early-stage-nsclc
- Start Date: 2024-07-17 05:00:00
- End Date: 2024-07-17 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 12666.67 - Is Kind Support: False Source: Genentech (Any division) - Amount: 41666.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest